| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.0091 | 0.9 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |